Loading company…
molab.ai develops AI tools for designing and optimizing molecules for drug discovery.
Founded in 2022 and based in Munich, Germany, molab.ai develops an AI-based drug discovery platform with molecular design, ADMET prediction, and compound optimization tools. Cresset, a portfolio company of Scottish Equity Partners, acquired the company from Picus Capital in July 2025.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in